Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Holding TSE:MDP?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
0.01Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2019
|% Change Since: 100.91%
|Next Earnings Date:Jul 18, 2018
Earnings Call Sentiment|Neutral
The earnings call reflected a mixed performance with strong profitability and cash flow, offset by revenue declines and challenges with certain products. The company's strategic adjustments and focus on future growth opportunities, such as treosulfan, are highlighted.Company Guidance
In the Medexus Pharmaceuticals' First Fiscal Quarter 2025 earnings call, executive Kenneth d'Entremont reported key financial metrics, highlighting a revenue of $27.3 million, a decrease from $31.6 million in the same period last year, and an adjusted EBITDA of $6.1 million, down from $6.6 million previously. Despite these declines, the company achieved a positive net income of $2 million, an increase of $1.3 million compared to the previous year, and a positive operating income of $4 million. The call emphasized the impact of cost reduction initiatives on operating costs, a 17% increase in Rupall unit demand in Canada, and a 6% decrease in IXINITY demand in the U.S. Medexus also anticipates a potential FDA decision for treosulfan by October 30, 2024, with hopes of achieving over $100 million in annual revenue within five years post-launch. The company's financial stability was further supported by a record operating cash flow of $8.2 million and cash on hand of $8.5 million as of June 30, 2024.Positive Net Income and EBITDA
Achieved positive net income of $2 million, an improvement of $1.3 million over the previous year, and strong adjusted EBITDA of $6.1 million.
Rupall's Strong Performance
Rupall unit demand in Canada increased by 17% over the trailing 12-month period ending June 30, 2024, significantly contributing to revenue during the allergy season.
Record Operating Cash Flow
Generated record quarterly operating cash flow of $8.2 million, driving positive cash flow for fiscal Q1 2025.
Metoject Growth
Metoject unit demand increased by 11% in the trailing 12-month period ending June 30, 2024, despite direct generic competition.
---
TSE:MDP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:MDP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | C$2.20 | C$2.17 | -1.36% |
| Aug 07, 2024 | C$2.27 | C$2.46 | +8.37% |
| Jun 25, 2024 | C$1.69 | C$1.72 | +1.78% |
| Feb 07, 2024 | C$2.70 | C$1.92 | -28.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Medexus Pharmaceuticals Inc (TSE:MDP) report earnings?
Medexus Pharmaceuticals Inc (TSE:MDP) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is Medexus Pharmaceuticals Inc (TSE:MDP) earnings time?
Medexus Pharmaceuticals Inc (TSE:MDP) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:MDP EPS forecast?
TSE:MDP EPS forecast for the fiscal quarter 2025 (Q3) is 0.01.
---